Intercontinental Exchange, Inc. (NYSE: ICE), a leading global provider of data, technology and market infrastructure, today announced the annual reconstitution of the ICE Biotechnology Index (ICEBIO), which is effective before the open of trading on Monday, December 20, 2021.
The ICE Biotechnology Index tracks the performance of qualifying U.S. listed biotechnology companies classified within the Biotechnology Sub-Industry Group of the ICE Uniform Sector Classification schema, which is a multi-asset class industry classification taxonomy developed by ICE. The index includes companies that are engaged in the research and development of therapeutic treatments but are not focused on the commercialization and mass production of pharmaceutical drugs. The index also includes companies that are engaged in the production of tools or systems that enable biotechnology processes.
“This annual reconstitution ensures that the index maintains its representation of the broader biotechnology industry,” said Aram Flores, Head of Index and Analytics at ICE. “By including companies meeting a minimum threshold of market capitalization and liquidity from multiple U.S. exchanges, the index provides a better gauge of the biotechnology industry and helps improve the investability for users benchmarking to the index.”
The following companies will be added to and removed from the index in the December 2021 annual reconstitution:
Ticker |
Name |
Action |
ABCL |
AbCellera Biologics, Inc. |
Addition |
ABCM |
Abcam PLC Sponsored ADR |
Addition |
ABOS |
Acumen Pharmaceuticals, Inc. |
Addition |
ABSI |
Absci Corporation |
Addition |
ACET |
Adicet Bio Inc |
Addition |
ACHL |
Achilles Therapeutics PLC Sponsored ADR |
Addition |
ACRS |
Aclaris Therapeutics, Inc. |
Addition |
ADMA |
ADMA Biologics, Inc. |
Addition |
AKUS |
Akouos, Inc. |
Addition |
AKYA |
Akoya Biosciences Inc |
Addition |
ALGS |
Aligos Therapeutics, Inc. |
Addition |
ALPN |
Alpine Immune Sciences, Inc. |
Addition |
ALVR |
AlloVir Inc |
Addition |
AMPE |
Ampio Pharmaceuticals, Inc. |
Addition |
ANVS |
Annovis Bio Inc |
Addition |
ATAI |
ATAI Life Sciences N.V. |
Addition |
ATHA |
Athira Pharma, Inc. |
Addition |
AUPH |
Aurinia Pharmaceuticals Inc. |
Addition |
AUTL |
Autolus Therapeutics Plc Sponsored ADR |
Addition |
AVIR |
Atea Pharmaceuticals, Inc. |
Addition |
AVTE |
Aerovate Therapeutics, Inc. |
Addition |
AVXL |
Anavex Life Sciences Corp. |
Addition |
BCAB |
BioAtla, Inc. |
Addition |
BCYC |
Bicycle Therapeutics Plc Sponsored ADR |
Addition |
BLU |
BELLUS Health Inc. |
Addition |
BMEA |
Biomea Fusion Inc |
Addition |
BNR |
Burning Rock Biotech Ltd. Sponsored ADR Class A |
Addition |
BOLT |
Bolt Biotherapeutics, Inc. |
Addition |
BTX |
Brooklyn ImmunoTherapeutics, Inc. |
Addition |
CADL |
Candel Therapeutics, Inc. |
Addition |
CCCC |
C4 Therapeutics, Inc. |
Addition |
CDAK |
Codiak BioSciences, Inc. |
Addition |
CGEM |
Cullinan Oncology, Inc. |
Addition |
CLSD |
Clearside Biomedical, Inc. |
Addition |
CMPS |
COMPASS Pathways Plc Sponsored ADR |
Addition |
CMRX |
Chimerix, Inc. |
Addition |
CNTA |
Centessa Pharmaceuticals PLC ADR |
Addition |
CNTB |
Connect Biopharma Holdings Ltd. Sponsored ADR |
Addition |
CRBU |
Caribou Biosciences, Inc. |
Addition |
CRIS |
Curis, Inc. |
Addition |
CTKB |
Cytek Biosciences, Inc. |
Addition |
CVAC |
CureVac N.V. |
Addition |
CYBN |
Cybin, Inc. |
Addition |
CYT |
Cyteir Therapeutics, Inc. |
Addition |
DAWN |
Day One Biopharmaceuticals, Inc. |
Addition |
DBTX |
Decibel Therapeutics, Inc. |
Addition |
DBVT |
DBV Technologies SA Sponsored ADR |
Addition |
DNAY |
Codex DNA, Inc. |
Addition |
DSGN |
Design Therapeutics, Inc. |
Addition |
DYN |
Dyne Therapeutics Inc |
Addition |
ERAS |
Erasca, Inc. |
Addition |
ETNB |
89bio Inc |
Addition |
EVLO |
Evelo Biosciences, Inc. |
Addition |
EWTX |
Edgewise Therapeutics, Inc. |
Addition |
FDMT |
4D Molecular Therapeutics, Inc. |
Addition |
GLUE |
Monte Rosa Therapeutics, Inc. |
Addition |
GRCL |
Gracell Biotechnologies Inc. Sponsored ADR Class A |
Addition |
GRPH |
Graphite Bio, Inc. |
Addition |
GRTS |
Gritstone bio, Inc. |
Addition |
GTH |
Genetron Holdings Ltd Sponsored ADR |
Addition |
HBIO |
Harvard Bioscience, Inc. |
Addition |
HOWL |
Werewolf Therapeutics, Inc. |
Addition |
HUMA |
Humacyte, Inc. |
Addition |
ICVX |
Icosavax, Inc. |
Addition |
IKNA |
Ikena Oncology, Inc. |
Addition |
IMGO |
Imago BioSciences, Inc. |
Addition |
IMMP |
Immutep Ltd Sponsored ADR |
Addition |
IMPL |
Impel NeuroPharma, Inc. |
Addition |
IMRX |
Immuneering Corp. Class A |
Addition |
INBX |
Inhibrx Inc |
Addition |
INFI |
Infinity Pharmaceuticals, Inc. |
Addition |
IPHA |
Innate Pharma SA Sponsored ADR |
Addition |
IPSC |
Century Therapeutics, Inc. |
Addition |
JANX |
Janux Therapeutics, Inc. |
Addition |
KMDA |
Kamada Ltd |
Addition |
KMPH |
KemPharm, Inc. |
Addition |
KNTE |
Kinnate Biopharma, Inc. |
Addition |
KRON |
Kronos Bio Inc |
Addition |
KYMR |
Kymera Therapeutics, Inc. |
Addition |
LABP |
Landos Biopharma, Inc. |
Addition |
LCTX |
Lineage Cell Therapeutics, Inc. |
Addition |
LPTX |
Leap Therapeutics, Inc. |
Addition |
LYEL |
Lyell Immunopharma, Inc. |
Addition |
MBIO |
Mustang Bio, Inc. |
Addition |
MIRM |
Mirum Pharmaceuticals, Inc. |
Addition |
MORF |
Morphic Holding, Inc. |
Addition |
MREO |
Mereo BioPharma Group plc Sponsored ADR |
Addition |
MRUS |
Merus N.V. |
Addition |
MRVI |
Maravai LifeSciences Holdings Inc Class A |
Addition |
MTEM |
Molecular Templates, Inc. |
Addition |
MTNB |
Matinas BioPharma Holdings, Inc. |
Addition |
MXCT |
MaxCyte, Inc. |
Addition |
NAUT |
Nautilus Biotechnolgy, Inc. |
Addition |
NRXP |
NRX Pharmaceuticals, Inc. |
Addition |
NUVB |
Nuvation Bio Inc Class A |
Addition |
NUVL |
Nuvalent, Inc. Class A |
Addition |
OBSV |
ObsEva SA |
Addition |
OCX |
Oncocyte Corporation |
Addition |
OLK |
Olink Holding AB Sponsored ADR |
Addition |
OLMA |
Olema Pharmaceuticals, Inc. |
Addition |
OMGA |
Omega Therapeutics, Inc. |
Addition |
OMIC |
Singular Genomics Systems, Inc. |
Addition |
ONCR |
Oncorus, Inc. |
Addition |
OYST |
Oyster Point Pharma Inc |
Addition |
PCVX |
Vaxcyte, Inc. |
Addition |
PHAT |
Phathom Pharmaceuticals, Inc. |
Addition |
PMVP |
PMV Pharmaceuticals, Inc. |
Addition |
PRAX |
Praxis Precision Medicines, Inc. |
Addition |
PRLD |
Prelude Therapeutics, Inc. |
Addition |
PRQR |
ProQR Therapeutics N.V. |
Addition |
RAIN |
Rain Therapeutics Inc |
Addition |
RANI |
Rani Therapeutics Holdings, Inc. Class A |
Addition |
RLYB |
Rallybio Corporation |
Addition |
ROIV |
Roivant Sciences Ltd. |
Addition |
RXDX |
Prometheus Biosciences, Inc |
Addition |
RXRX |
Recursion Pharmaceuticals, Inc Class A |
Addition |
SANA |
Sana Biotechnology, Inc. |
Addition |
SBTX |
Silverback Therapeutics, Inc. |
Addition |
SEER |
Seer, Inc. Class A |
Addition |
SESN |
Sesen Bio, Inc. |
Addition |
SLDB |
Solid Biosciences Inc. |
Addition |
SMMT |
Summit Therapeutics Inc |
Addition |
SNSE |
Sensei Biotherapeutics, Inc. |
Addition |
SQZ |
SQZ Biotechnologies Company |
Addition |
STTK |
Shattuck Labs, Inc. |
Addition |
STVN |
Stevanato Group SpA |
Addition |
SYNH |
Syneos Health, Inc. Class A |
Addition |
TALS |
Talaris Therapeutics, Inc. |
Addition |
TERN |
Terns Pharmaceuticals, Inc. |
Addition |
TIL |
Instil Bio, Inc. |
Addition |
TKNO |
Alpha Teknova, Inc. |
Addition |
TNYA |
Tenaya Therapeutics, Inc. |
Addition |
TSHA |
Taysha Gene Therapies, Inc. |
Addition |
VERV |
Verve Therapeutics, Inc. |
Addition |
VIRX |
Viracta Therapeutics, Inc. |
Addition |
VOR |
Vor Biopharma, Inc. |
Addition |
VRCA |
Verrica Pharmaceuticals Inc. |
Addition |
AMRS |
Amyris, Inc. |
Deletion |
APRE |
Aprea Therapeutics, Inc. |
Deletion |
ARDX |
Ardelyx, Inc. |
Deletion |
ASMB |
Assembly Biosciences, Inc. |
Deletion |
BCEL |
Atreca, Inc. Class A |
Deletion |
CALA |
Calithera Biosciences, Inc. |
Deletion |
CERS |
Cerus Corporation |
Deletion |
CNCE |
Concert Pharmaceuticals, Inc. |
Deletion |
EGRX |
Eagle Pharmaceuticals, Inc. |
Deletion |
ESPR |
Esperion Therapeutics, Inc. |
Deletion |
GH |
Guardant Health, Inc. |
Deletion |
INZY |
Inozyme Pharma, Inc. |
Deletion |
KALA |
Kala Pharmaceuticals, Inc. |
Deletion |
KLDO |
Kaleido Biosciences, Inc. |
Deletion |
MNOV |
MediciNova, Inc. |
Deletion |
MOR |
MorphoSys AG Sponsored ADR |
Deletion |
NCNA |
NuCana plc Sponsored ADR |
Deletion |
ODT |
Odonate Therapeutics, Inc. |
Deletion |
OMER |
Omeros Corporation |
Deletion |
SIGA |
SIGA Technologies Inc |
Deletion |
SUPN |
Supernus Pharmaceuticals, Inc. |
Deletion |
TLSA |
Tiziana Life Sciences Ltd. |
Deletion |
UBX |
Unity Biotechnology, Inc. |
Deletion |
VRNA |
Verona Pharma plc Sponsored ADR |
Deletion |
VYGR |
Voyager Therapeutics, Inc. |
Deletion |
XBIT |
XBiotech, Inc. |
Deletion |
ICE’s global family of indices serve as the performance benchmark for more than $1 trillion in assets managed by investors around the globe. For more information about ICE’s Indices, please visit: https://www.ice.com/market-data/indices.
About Intercontinental Exchange
Intercontinental Exchange, Inc. (NYSE: ICE) is a Fortune 500 company that designs, builds and operates digital networks to connect people to opportunity. We provide financial technology and data services across major asset classes that offer our customers access to mission-critical workflow tools that increase transparency and operational efficiencies. We operate exchanges, including the New York Stock Exchange, and clearing houses that help people invest, raise capital and manage risk across multiple asset classes. Our comprehensive fixed income data services and execution capabilities provide information, analytics and platforms that help our customers capitalize on opportunities and operate more efficiently. At ICE Mortgage Technology, we are transforming and digitizing the U.S. residential mortgage process, from consumer engagement through loan registration. Together, we transform, streamline and automate industries to connect our customers to opportunity.
Trademarks of ICE and/or its affiliates include Intercontinental Exchange, ICE, ICE block design, NYSE and New York Stock Exchange. Information regarding additional trademarks and intellectual property rights of Intercontinental Exchange, Inc. and/or its affiliates is located here. Key Information Documents for certain products covered by the EU Packaged Retail and Insurance-based Investment Products Regulation can be accessed on the relevant exchange website under the heading “Key Information Documents (KIDS).”
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995 -- Statements in this press release regarding ICE's business that are not historical facts are "forward-looking statements" that involve risks and uncertainties. For a discussion of additional risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements, see ICE's Securities and Exchange Commission (SEC) filings, including, but not limited to, the risk factors in ICE's Annual Report on Form 10-K for the year ended December 31, 2020, as filed with the SEC on February 4, 2021.
SOURCE: Intercontinental Exchange
ICE-CORP
View source version on businesswire.com: https://www.businesswire.com/news/home/20211216005424/en/
Contacts
ICE Media Contact:
Damon Leavell
damon.leavell@ice.com
(212) 323-8587
ICE Investor Contact:
Mary Caroline O’Neal
marycaroline.oneal@ice.com
(770) 738-2151
